Trials / Completed
CompletedNCT00795522
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria (Study P02540)
An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- Organon and Co · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label study is being conducted to determine the effect of DL treatment for CIU on symptom and disease severity, quality of life, daytime functioning, and quality of sleep.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Desloratadine | Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine |
Timeline
- Start date
- 2003-07-01
- Primary completion
- 2005-02-01
- Completion
- 2005-03-01
- First posted
- 2008-11-21
- Last updated
- 2022-02-17
Source: ClinicalTrials.gov record NCT00795522. Inclusion in this directory is not an endorsement.